Early Clinically Important Improvement (ECII) and exacerbation outcomes in the FLAME study

K. Kostikas (Basel, Switzerland), A. Mackay (London, United Kingdom), C. Vogelmeier (Marburg, Germany), S. Frent (Timisoara, Romania), P. Pfister (Basel, Switzerland), P. Gupta (Hyderabad, India), D. Banerji (East Hanover, United States of America), F. Patalano (Basel, Switzerland), J. Wedzicha (London, United Kingdom)

Source: International Congress 2018 – Clinical trials in COPD: new results
Session: Clinical trials in COPD: new results
Session type: Oral Presentation
Number: 1657
Disease area: Airway diseases

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
K. Kostikas (Basel, Switzerland), A. Mackay (London, United Kingdom), C. Vogelmeier (Marburg, Germany), S. Frent (Timisoara, Romania), P. Pfister (Basel, Switzerland), P. Gupta (Hyderabad, India), D. Banerji (East Hanover, United States of America), F. Patalano (Basel, Switzerland), J. Wedzicha (London, United Kingdom). Early Clinically Important Improvement (ECII) and exacerbation outcomes in the FLAME study. 1657

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: